CAS NO: | 57381-26-7 |
规格: | ≥98% |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
2g | 电议 |
5g | 电议 |
10g | 电议 |
Molecular Weight (MW) | 256.09 |
---|---|
Formula | C9H7Cl2N5 |
CAS No. | 57381-26-7 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 2 mg/mL (7.8 mM) |
Water:<1 mg/mL | |
Ethanol: <1 mg/mL | |
Other info | Chemical Name: 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine SMILES Code: NC1=NC(N)=NC(C2=CC(Cl)=CC=C2Cl)=N1 |
Synonyms | MN1695; MN 1695; Gaslon; MN-1695; Irsogladine maleate; |
In Vitro | In vitro activity: Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy. Irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions |
---|---|
In Vivo | Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice. |
Animal model | Mice |
Formulation & Dosage | 300 and 500 mg/kg |
References | J Surg Res. 1998 Jul 1;77(2):126-31; Pancreas. 2002 Nov;25(4):373-7; Life Sci. 2004 Aug 27;75(15):1833-42. |